Marie Galvao
Nurse Practitioner · Bronx, NYNPI 1467542365
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 61.1% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2021 at $8,210 and has fallen 88.8% since, to $923 in 2025. Among nurse practitioner clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 81 payments — averaging $243.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$12K
- Merck$3K
- Impulse Dynamics (USA) Inc.$2K
- Novartis$585
- Cvrx, Inc.$562
- Scpharmaceuticals Inc.$204
- plus $809 from 9 others
What the payments were for
- Consulting fees$5,10626%
- Speaking & faculty fees$10,50053%
- Travel & lodging$1,98510%
- Food & beverage$2,08811%
- Education$700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 13 | $12,073 |
| Merck | 8 | $3,188 |
| Impulse Dynamics (USA) Inc. | 4 | $2,328 |
| Novartis | 8 | $585 |
| Cvrx, Inc. | 6 | $562 |
| Scpharmaceuticals Inc. | 6 | $204 |
| Alnylam Pharmaceuticals Inc. | 3 | $166 |
| Bristol Myers Squibb | 14 | $160 |
| Abbott | 6 | $138 |
| Actelion Pharmaceuticals US, Inc. | 3 | $124 |
| E.r. Squibb & Sons, L.L.C. | 5 | $87 |
| Johnson & Johnson | 1 | $50 |
| Pfizer | 2 | $31 |
| Endotronix, Inc. | 1 | $28 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$9,450
- OPTIMIZER$4,519
- CLINICAL TRIAL PRODUCT$1,069
- VERQUVO$508
- Barostim Neo System$413
- LEQVIO$315
- ENTRESTO$215
- ONPATTRO$135
- FUROSCIX$118
How this compares
$19,749 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 570 | $600,936 |
| VyndamaxTafamidis | 12 | $378,546 |
| FarxigaDapagliflozin Propanediol | 237 | $211,208 |
| EliquisApixaban | 178 | $181,182 |
| JardianceEmpagliflozin | 144 | $141,715 |
| LokelmaSodium Zirconium Cyclosilicate | 28 | $28,591 |
| VerquvoVericiguat | 30 | $22,534 |
| Repatha SureclickEvolocumab | 11 | $15,303 |
| CorlanorIvabradine Hcl | 12 | $14,552 |
| VascepaIcosapent Ethyl | 35 | $13,478 |
| NexlizetBempedoic Acid/Ezetimibe | 21 | $11,770 |
| BrilintaTicagrelor | 15 | $9,112 |
| Praluent PenAlirocumab | 11 | $8,587 |
| Metoprolol Succinate | 528 | $8,504 |
| Isosorbide Dinitrate | 129 | $6,818 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $585 | $600,936570 claims |
| PfizerVyndamax, Eliquis | $31 | $559,729190 claims |
| MerckVerquvo | $3,188 | $22,53430 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.
Other nurse practitioner in Bronx
- Una HopkinsBronx$26K
- Patricia McGoldrickNew York$202K
- Michelle DartSyracuse$95K
- Susan KreppelWilliamsville$67K
- Kerry AhernEast Syracuse$55K
- Valerie StanleyAlbany$55K
- Jodi LogerfoNew York$48K
- Grace WlasowiczRochester$41K
- Melissa LevinElmhurst$34K
- Carla JungquistCanandaigua$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.